Person Responsible for Regulatory Compliance (PPRC) under MDR & IVDR
The EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Device Regulation (EU IVDR) require all Manufacturers and Authorized Representatives to have a designated employee in their company who is responsible for regulatory compliance with the applicable MDR or IVDR requirements, the Person Responsible for Regulatory Compliance (PRRC).

WHAT ARE THE RESPONSIBILITIES OF THE PRRC?

The person responsible for regulatory compliance, permanently and continuously at disposal, shall at least be responsible for ensuring:

  1. the conformity of the devices is appropriately checked, in accordance with the quality management system (QMS) under which the devices are manufactured, before a device is released;
  2. the technical documentation and the EU declaration of conformity are drawn up and kept up-to-date;
  3. the post-market surveillance obligations are complied with in accordance with Article 10(10) of MDR and Article 10(9) of IVDR;
  4. the reporting obligations referred to in Articles 87-91 of MDR and Articles 82-86 of IVDR;
  5. in the case of investigational devices, the statement referred to in Section 4.1 of Chapter II of Annex XV of the MDR and Section 4.1 of Annex XIV of the IVDR.

The Manufacturer or Authorized Representative may appoint more than one PRRC. In this case, their respective areas of responsibility shall be put down in writing.

WHAT ARE THE QUALIFICATIONS OF THE PRRC?

Article 15(1) of both MDR and IVDR require the PRRC to have either:

  • A diploma, certificate or other evidence of formal qualification, awarded on completion of a university degree or of a course of study recognized as equivalent by the Member State concerned, in law, medicine, pharmacy, engineering or another relevant scientific discipline, and at least one year of professional experience in regulatory affairs or in quality management systems relating to medical devices or in vitro diagnostics.
  • 4 years of professional experience in regulatory affairs or in quality management systems in the medical device or in vitro diagnostic device fields.

The MDCG Guidance 2019-7 specifies that the professional experience in regulatory affairs or quality management should be related to the EU requirements in the field. Additionally, for manufacturers located outside the EU, it must be assumed that the PRRC should also be located outside the EU. On the other hand, for manufacturers located in the EU, it must be assumed that the PRRC should also be located in the EU.

It is important to note that the PRRC does not replace the manufacturer’s European Authorized Representative (EC REP) as these are two separate roles with different responsibilities and obligations under the MDR and IVDR.

The PRRC appointed should be an employee of the organization. Micro and small enterprises, e.g., with fewer than 50 full-time employees and less than €10 million in global sales are not required to have the PRRC within their organization and can outsource this role to a third party, while ensuring that such person is permanently and continuously at their disposal.

If you wish to know more information about the EU Medical Device Regulation (EU MDR) and the EU In Vitro Diagnostic Device Regulation (EU IVDR) feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (UE) 2017/745, on medical devices
  2. Regulation (UE) 2017/746, on in vitro diagnostic medical devices
  3. MDCG 2019-7 – Guidance on Article 15 of the Medical Device Regulation (MDR) and in vitro Diagnostic Device Regulation (IVDR) regarding a ‘person responsible for regulatory compliance’ (PRRC)

further
reading

medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »